Hypertension and dyslipidaemia are important components of metabolic syndrome and both are known to complicate each other. Materials and Methods. A total of 149 subjects consisting of 107 hypertensive patients, grouped into 3 (of 37, 35, and 35 patients categorized based on the grade of hypertension as grade 1, grade 2, and grade 3, resp.) and 42 controls, were recruited for this study. Each subject had a recording of the bio- and anthropometric data comprising of the age, height, weight, body mass index (BMI), and abdominal circumference (AC). The blood pressure was also recorded. Fasting blood was collected and serum was used for the estimation of the lipids: total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and triglyceride (TG), while low density lipoprotein cholesterol (LDL-C) and VLDL were estimated using Friedewald formula. Findings. Patients with hypertension had higher lipid and lipoprotein levels than the controls and the values became more significant with increasing severity of hypertension. The difference was statistically significant for TC, LDL-C, and VLDL-C ( ). Conclusion. This study showed that lipid and lipoprotein cholesterol abnormalities exist and even worsen with severity of hypertension. It is important that investigations in patients with hypertension should include a lipid profile. 1. Introduction Hypertension and dyslipidaemia were among the notable risk factors implicated in various cardiovascular events [1–3] both being important modifiable components of metabolic syndrome [4]. Of all the various risk factors for cardiovascular events, the association of hypertension and dyslipidaemia is the commonest [5] though the actual prevalence is not well known. Various studies have explored the association of hypertension and dyslipidaemia [5–7] but the definite pattern or changes with regard to the severity of hypertension is still largely lacking in reports. Moreover since lipid and lipoprotein indices were common complications of hypertension and/or its treatment [8–10] adequate investigations form the bed-rock of effective patient management [11, 12]. This study was designed to provide the baseline lipid and lipoprotein levels in relation to the severity of hypertension. The knowledge is important because it makes both the clinician and the patient wiser on the lipid risk factor status, in the choice of appropriate antihypertensive medication suitable for the patient, and lastly to recommend strategies aimed at retarding the progression of atherosclerotic process in hypertensive patients. 2. Materials and
References
[1]
“Coronary artery disease,” in Non-Commucable Disease in Nigeria, O. O. Akinkugbe, Ed., vol. 2 of 1, pp. 13–22, 1992.
[2]
J. M. Gaziano, H. D. Sesso, J. L. Breslow, C. H. Hennekens, and J. E. Buring, “Relation between systemic hypertension and blood lipids on the risk of myocardial infarction,” American Journal of Cardiology, vol. 84, no. 7, pp. 768–773, 1999.
[3]
V. Hachinski, C. Graffagnino, M. Beaudry et al., “Lipids and stroke: a paradox resolved,” Archives of Neurology, vol. 53, no. 4, pp. 303–308, 1996.
[4]
B. C. Hansen, “The metabolic syndrome X,” Annals of the New York Academy of Sciences, vol. 892, pp. 1–24, 1999.
[5]
M. J. Landray, E. Edmunds, F. L. Li-Saw-Hee et al., “Abnormal low-density lipoprotein subfraction profile in patients with untreated hypertension,” The Quarterly Journal of Medicine, vol. 95, no. 3, pp. 165–171, 2002.
[6]
M. J. Landray, G. Sagar, J. Muskin, S. Murray, R. L. Holder, and G. Y. H. Lip, “Association of atherogenic low-density lipoprotein subfractions with carotid atherosclerosis,” The Quarterly Journal of Medicine, vol. 91, no. 5, pp. 345–351, 1998.
[7]
A. Gnasso, M. C. Calindro, C. Carallo et al., “Awareness, treatment and control of hyperlipidaemia, hypertension and diabetes mellitus in a selected population of southern Italy,” European Journal of Epidemiology, vol. 13, no. 4, pp. 421–428, 1997.
[8]
E. Edmunds, M. J. Landray, F. L. Li-Saw-Hee, B. A. Hughes, D. G. Beevers, and G. Y. H. Lip, “Dyslipidaemia in patients with malignant-phase hypertension,” The Quarterly Journal of Medicine, vol. 94, no. 6, pp. 327–332, 2001.
[9]
J. E. Ahaneku, G. O. Taylor, E. O. Agbedana, O. Walker, and L. A. Salako, “Changes in lipid and lipoprotein values during a cross-over treatment of doxazosin, moduretic and amlodipine in hypertensive patients,” Journal of the Pakistan Medical Association, vol. 444, no. 7, pp. 166–169, 1994.
[10]
A. O. Falase, L. A. Salako, and A. F. Aderounmu, “Beta-adrenergic receptor blockers in the of hypertension: a trial of pindolol in Africans,” Cardiologic Tropicale, vol. 11, pp. 111–120, 1972.
[11]
J. E. Ahaneku, M. C. Nwosu, G. I. Ahaneku, and P. C. Okugba, “Underutilization of lipid profile investigations in disease management in Nigeria,” East African Medical Journal, vol. 76, no. 3, pp. 46–49, 1999.
[12]
C. Borghi, A. Dormi, M. Veronesi, Z. Sangiorgi, and A. Gaddi, “Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study,” American Heart Journal, vol. 148, no. 2, pp. 285–292, 2004.
[13]
World Health Organization, “International Society of Hypertension: guideline for management of hypertension. Guideline subcommittee,” Journal of Hypertension, vol. 17, pp. 151–183, 1999.
[14]
S. K. Lwanga and E. Tye, Teaching Health Statistics. Twenty Lessons and Seminars, vol. 70, World Health Organization, Geneva, Switzerland, 1986.
[15]
The Guideline Sub-Committee for the WHO-ISH Mild Hypertension Laison Committee, “Guidelines for the management of mild hypertension. Mild hypertension memorandum for a World Health Organisation—international society of hypertension meeting,” Journal of Hypertension, vol. 11, pp. 905–918, 1993.
[16]
J. I. Cleeman, “Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III),” Journal of the American Medical Association, vol. 285, no. 19, pp. 2486–2497, 2001.
[17]
M. Mackness and P. N. Durrington, “Lipopritein separation and analysis for clinical studies,” in Lipoprotein Analysis. Practical Approach, C. A. Converse and E. R. Skinner, Eds., pp. 1–42, Oxford University Press, New York, NY, USA, 1st edition, 1992.
[18]
G. R. Warinck, Methods in Enzymology, vol. 129, Academic Press, London, UK, 1986.
[19]
H. K. Naito and J. A. David, Lipid Research Methodology, vol. 1, Alan R. Liss, New York, NY, USA, 1984.
[20]
W. T. Friedewald, R. I. Levy, and D. S. Fredrickson, “Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge,” Clinical Chemistry, vol. 18, no. 6, pp. 499–502, 1972.
[21]
O. Aduba, I. Onwuamaeze, J. Oli, and K. Udeozo, “Serum cholesterol and high density lipoprotein cholesterol in Nigerian diabetics,” East African Medical Journal, vol. 61, no. 1, pp. 35–39, 1984.
[22]
G. O. Taylor, “Studies of serum lipids in Nigeria,” Tropical and Geographical Medicine Journal, vol. 23, pp. 158–166, 1971.
[23]
G. O. Taylor and E. O. Agbedana, “A comparative study of plasma high-density lipoprotein cholesterol in two groups of Nigerians of different socio-economic status,” African Journal of Medicine and Medical Sciences, vol. 12, no. 1, pp. 23–28, 1983.
[24]
Y. K. Seedat and F. G. H. Mayet, “Risk factors leading to coronary heart disease among the Black, Indian and White peoples of Durban,” Journal of Human Hypertension, vol. 10, supplement 3, pp. S93–S94, 1996.
[25]
I. Hjermann, “The metabolic cardiovascular syndrome: syndrome X, reaven's syndrome, insulin resistance syndrome, atherothrombogenic syndrome,” Journal of Cardiovascular Pharmacology, vol. 20, supplement 8, pp. S5–S10, 1992.
[26]
C. Bruce, R. A. Chouinard Jr., and A. R. Tall, “Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport,” Annual Review of Nutrition, vol. 18, pp. 297–330, 1998.
[27]
S. M. Grundy, “Age as a risk factor: you are as old as your arteries,” American Journal of Cardiology, vol. 83, no. 10, pp. 1455–1457, 1999.
[28]
R. M. J. Palmer, A. G. Ferrige, and S. Moncada, “Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor,” Nature, vol. 327, no. 6122, pp. 524–526, 1987.
